Josh Xiao

Josh wears two hats at 23andMe with responsibilities over both leading Biomarker Discovery as well as leading therapeutic program focused on small molecules. Josh has over 19 years of biotech experience, a decade of work in small molecule drug development and close to ten years focused on antibody drug discovery. Josh joins us from Affinita Biotech, where he was a Principal Scientist of Translational Sciences. In this role, Josh managed and led in vivo studies of an oncology antibody program, the development of a companion diagnostic assay. Before that, Josh worked in Amgen as a Principal Scientist of Oncology Research, where he led several antibody drug discovery programs, and before moved to Oncology, Josh lead Amgen’s HTS and Molecular Pharmacology group at its South San Francisco site. Josh started his biotech career at Millennium Pharmaceuticals, where he was a Scientist in Lead Discovery. Josh earned his Ph.D. in Biochemistry from Louisiana State University and completed his post-doctoral work at Columbia University.